Start Submission Become a Reviewer

Reading: Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable panc...

Download

A- A+
Alt. Display

Case Series

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma

Authors:

Paul Toomey,

Florida Hospital Tampa, Tampa, FL, US
About Paul

MD

X close

Anthony Teta,

Florida Hospital Tampa, Tampa, FL, US
About Anthony

BS

X close

Krishen Patel,

Florida Hospital Tampa, Tampa, FL, US
About Krishen

BS

X close

Darrell Downs,

Florida Hospital Tampa, Tampa, FL, US
About Darrell

BS

X close

Kenneth Luberice,

Florida Hospital Tampa, Tampa, FL, US
About Kenneth

MS

X close

Sharona Ross,

Florida Hospital Tampa, Tampa, FL, US
About Sharona

MD

X close

Alexander S. Rosemurgy

Florida Hospital Tampa, 3000 Medical Park Drive, Suite 500, Tampa, FL, US
About Alexander S.

MD

X close

Abstract

Introduction: Patients with pancreatic adenocarcinoma have an increased propensity for diabetes. Recent studies suggest patients with diabetes and pancreatic adenocarcinoma treated with metformin have increased survival. This study was undertaken to determine whether metformin use is associated with increased survival in patients with pancreatic adenocarcinoma.

Methods: Patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma from 1991 to 2013 were included in this study. Survival was evaluated by Kaplan-Meier analysis. Median data are reported. Significance was accepted with 95% probability.

Results: Of 414 patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma, 132 (32%) were diabetic. Of patients with diabetes, 35 (27%) were diet-controlled, 34 (26%) were treated with insulin alone, 18 (14%) were treated with metformin alone, 14 (10%) were treated with sulfonylureas alone, 7 (5%) were taking sulfonylureas with insulin, and 24 (18%) patients were taking metformin with sulfonylureas and/or insulin. Patients with/without diabetes not taking sulfonylureas had survival of 16.4 months compared with patients taking sulfonylureas who achieved survival of 27.5 months after undergoing pancreaticoduodenectomy (P< 0.05).

Conclusions: Patients taking sulfonylureas with or without other therapy had improved survival compared with patients not taking sulfonylureas after pancreaticoduodenectomy. Metformin does not seem to be beneficial for patients with resectable disease, but may be beneficial for patients with unresectable and/or metastatic disease as shown in prior studies. The use of sulfonylureas is associated with a survival benefit for patients undergoing resection for pancreatic adenocarcinoma. Tumor staging and margin status continue to be the overriding predictors of survival in patients with resectable pancreatic adenocarcinoma, not metformin therapy.

How to Cite: Toomey P, Teta A, Patel K, Downs D, Luberice K, Ross S, et al.. Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma. International Journal of Surgery: Oncology. 2017;2(3):e15. DOI: http://doi.org/10.1097/IJ9.0000000000000015
Published on 07 Apr 2017.
Peer Reviewed

Downloads

  • PDF (EN)